Memorial Sloan Kettering spinout Paige’s series B total stands at $70m following a third tranche featuring Goldman Sachs and Healthcare Venture Partners.

3B Future Health Fund has participated in the cancer drug developer’s $5.8m extension round, investing alongside returning backers including M Ventures.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

A total of 23 biopharmaceutical producers have committed capital to the vehicle, which will provide funding for the creation of new antibiotics.

Neurodegenerative disease company Transquis has emerged from stealth with $30m in series A funding to advance research conducted at Stanford.

Eir’s first fund will partner Nordics-based universities to invest in their spinouts, while also making selected deals in the rest of Europe and the US.

Novo is among the limited partners for Eir Ventures, which has launched with $86m to invest in life sciences technology startups.

Eli Lilly and Horizon Therapeutics contributed to the life sciences venture firm's Forbion Growth Opportunities Fund, which will make late-stage investments.

NFP and Alphabet's GV unit contributed to a series B round that will help the fertility and gynaecology services startup expand its brick-and-mortar outlets.

The neurodegenerative disease startup has emerged from stealth with $30m taken in a series A round co-led by GlaxoSmithKline's SR One unit.